To cite: Nigam S, Sharma RK,

Yadav R. et al. Experiences

and needs of patients with

MDR/XDR-TB: a qualitative

tribe in Madhya Pradesh,

Central India. BMJ Open

bmjopen-2020-044698

2021;11:e044698. doi:10.1136/

Prepublication history and

for this paper are available

online. To view these files,

(http://dx.doi.org/10.1136/

bmjopen-2020-044698).

Accepted 27 July 2021

please visit the journal online

Received 14 September 2020

additional supplemental material

study among Saharia

BMJ Open Experiences and needs of patients with MDR/XDR-TB: a qualitative study among Saharia tribe in Madhya Pradesh, Central India

Samridhi Nigam,¹ Ravendra K Sharma,² Rajiv Yadav,¹ Vikas Gangadhar Rao,¹ Prashant Mishra,¹ Mercy Aparna Lingala,¹ Jyothi Bhat ¹

ABSTRACT

Background Drug-resistant tuberculosis (DR-TB) continues to be a major public health threat posing a critical challenge to TB treatment and control worldwide. The present study was conducted among patients with DR-TB of the Saharia tribe residing in Madhya Pradesh state of Central India to document their experiences and needs, and to identify gaps for treatment adherence as this population is known to be poor because of migration and other factors.

Methods We conducted 16 in-depth interviews on purposively selected patients with DR-TB among the Saharia tribe using a predesigned open-ended in-depth interview guide, which included questions on domains like general physical health, diagnosis, treatment adherence, side-effects of drugs and experience related to the health facility. Out of these interviews, various subthemes were extracted. The obtained qualitative data were subjected to thematic analysis.

Results The study helped to understand the experiences and needs of the patients with DR-TB in various stages from diagnosis to treatment. Also, there was the impact of factors like lack of education and awareness, poor living conditions and lack of healthcare facilities on predominance of the disease in the community. Poor access to a healthcare facility, high pill burden and related side-effects, longer duration of treatment, financial burden, misbeliefs and misconceptions were prominent issues posing a challenge to treatment adherence. The narratives pointed out their struggle at every stage be it with diagnosis, treatment initiation or treatment adherence. **Conclusion** It is paramount to address the needs and experiences of patients with DR-TB to develop a patientcentric and context-specific approach conducive to the sociocultural set-up of tribal people. This will scale down the attrition rate of tribal patients while adhering to the complete treatment process and reducing the high burden of TB among the Saharia community. In addition, tribal patients should be counselled at regular intervals to increase their confidence in the treatment.

INTRODUCTION

Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, remains one of the top 10 causes of death worldwide. Globally, an estimated

Strengths and limitations of this study

- The present study is a novel one exploring the needs and experiences of patients with multidrugresistant/extensively drug-resistant tuberculosis (MDR/XDR-TB) belonging to the Saharia tribe in Central India. This becomes particularly relevant since this population group falls in the particularly vulnerable tribal group segment.
- This study captures the attitude and acceptance of the treatment by the participants by giving them space to open up about the experiences they went through in the whole process of treatment.
- The study has incorporated many such experiences verbatim, which would rather be impossible to be captured through a quantitative study.
- The sample was purposive and may not entirely represent the experiences and needs of patients with MDR/XDR-TB in this community.
- Though it is advisable to follow people prospectively, the patients with DR-TB were interviewed for their perceptions and experiences about TB and the available treatment services retrospectively which may result in recall bias.

10 million people fell ill with TB in the year 2018.¹ The burden of the disease varies enormously among countries, from fewer than 5 to more than 500 new cases per 100 000 population per year, with the global average being around 130.1 The drug-resistant TB (DR-TB) continues to be a public health threat. In 2018, there were about half a million new cases of rifampicin-resistant TB (RR-TB), and India alone contributing about 27% of the world's DR-TB cases.¹ Globally, 3.4% of new TB cases and 18% of previously treated cases had multidrug-resistant TB (MDR-TB) or RR-TB.¹ Treatment success rate of patients with DR-TB was reported to be below 50% in India, which resulted in higher death rates.²³ Loss to treatment follow-up (LTFU) is the key issue in MDR-TB as these cases may remain

and permissions. Published by BMJ.

employer(s)) 2021. Re-use

permitted under CC BY-NC. No

commercial re-use. See rights

C Author(s) (or their

Check for updates

¹Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India ²ICMR- National Institute of Medical Statistics, New Delhi, Delhi, India

Correspondence to Dr Jyothi Bhat; drjyothibhat@rediffmail.com

BMJ

infectious, thus spreading the disease and also the possibility of developing further drug resistance among them. There is, however, very limited information available on the factors responsible for LTFU in MDR-TB in India, particularly among the tribal population.^{4–6}

There are over 700 Scheduled Tribes (STs) notified in India, spread over different states and Union Territories of the country. The state of Madhya Pradesh accounts for 21.1% of the ST population of India.⁷ The Saharia tribe one of the particularly vulnerable tribal group (PVTG)is mainly located in Gwalior and Chambal divisions of Madhya Pradesh and has the highest reported TB prevalence in the country ranging from 1270 to 3294 per 100 000 population.⁸⁻¹¹ The Saharia tribe is among the most vulnerable population segment that suffers from poverty and unhygienic/overcrowded living conditions. Most community members earn their livelihood as daily wage labourers or labourers in agriculture farms.⁸ Other factors that further increase the risk of TB infection include lack of education, poor access to healthcare facilities, high prevalence of alcohol and tobacco consumption as well as financial constraints. Though the directly observed treatment-short course (DOTS) is being implemented in the area, it also suffers from several constraints including shortages of health workers, irregular drug supplies and poor supervision by the staff. Lack of treatment adherence becomes even more significant in such a situation particularly among the Saharia tribal community with high TB burden.^{4 10 11} So, keeping all these facts and the robust decision of the government of India to eliminate TB by 2025, this study was conducted among patients with DR-TB of Saharia tribe residing in Madhya Pradesh state in Central India to document their experiences and needs, and to identify gaps for treatment adherence.

METHODS

Qualitative approach and research paradigm

The present qualitative research was conducted as a substudy of the main ongoing 'Intensified TB Control Project in Saharia tribe of Madhya Pradesh' which focuses on active case detection through engagement of community volunteers, prompt treatment, and follow-up of cases and health promotion or awareness activities. This project is ongoing in Saharia villages across even districts of the Chambal region, Madhya Pradesh state, where this tribe predominantly resides and encompasses about 0.5 million population.¹²

Study design and theoretical background/population sample

This research used a qualitative study design to identify the experiences and needs of people suffering from extensively drug-resistant (XDR)/MDR-TB in the PVTG. The interview was conducted in the place chosen by the participants without disturbing their routine or privacy. Before each in-depth interview, the participant's approval and comfort were given utmost importance.

Recruitment of participants

The qualitative study was conducted from July 2019 to August 2019 among patients with DR-TB belonging to this tribal group. There is no well-established guideline for estimation of sample size prior to the qualitative study and the study population is also very homogeneous, that is, patients with MDR/XDR-TB of Saharia tribe. We used the principle of saturation and repetition of information to decide the number of participants to be included in the study. In total, 16 participants, who were on anti-TB treatment or being recently treated and were available at the time of field visits, were enrolled through purposive sampling techniques irrespective of treatment duration. Informed consent was taken from each participant before the commencement of the interview.

Data collection technique

All patients were interviewed by a senior researcher with a postgraduate degree in public health and an experience of working in tribal communities. These interviews were carried out during routine field monitoring visits. The researcher is familiar with the local dialect of the Saharia tribe, however, the researcher does not belong to the tribal community. Data from participants were acquired through a preset of specific questions to get an insight into their sociodemographic details and living conditions.

Data collection tool

A predesigned open-ended in-depth interview guide was drafted in consultation with subject experts, clinicians and DOTS providers (available as online supplemental file). The in-depth interview guideline consisting of questions on various domains like general physical health, diagnosis, treatment adherence, side-effects of drugs and experience related to the health facility was used for interviewing the participants. However, the interview tool also had some structured questions related to background characteristics, like age, sex, education status, occupation and history/family history of TB. Audio-recording of the in-depth interviews was recorded simultaneously with prior permission from all the participants.

Data processing

For better comprehension, the interview was conducted in the local language spoken by the participants. The researcher used an audio-recording device for recording the interview and an interview took 30–45 min on average.

Data analysis procedure

All audio-recordings of participants were transcribed in Hindi language and then translated into English for data analysis by the researcher. The interview transcripts were coded, entered manually and analysed to generate themes. The extracted codes were further divided into various categories manually. Four main stages include familiarisation, identifying a thematic framework, coding and interpretation. Interviewer-related bias was addressed by continuously discussing and negotiating the content of keywords, concepts and meaning of verbatim

Table 1	Summ	Summary of patients with XDR/MDR-TB interviewed					
Sr no	Age	Sex	MDR/XDR	Education	Family type	History of TB in family	
P 1	50	Μ	XDR	No formal education	Extended	No	
P 2	48	Μ	XDR	No formal education	Extended	No	
P 3	44	Μ	XDR	Primary	Nuclear	No	
P 4	55	Μ	XDR	No formal education	Extended	No	
P 5	28	Μ	XDR	Primary	Extended	No	
P 6	36	М	MDR	Primary	Extended	No	
P 7	45	F	MDR	No formal education	Extended	No	
P 8	35	М	MDR	No formal education	Nuclear	Yes	
P 9	40	Μ	MDR	No formal education	Nuclear	Yes	
P 10	35	М	MDR	Primary	Nuclear	No	
P 11	37	Μ	MDR	No formal education	Nuclear	Yes	
P 12	60	F	MDR	No formal education	Nuclear	No	
P 13	18	Μ	MDR	High school	Extended	Yes	
P 14	40	Μ	MDR	Primary	Extended	No	
P 15	45	Μ	MDR	No formal education	Extended	Yes	
P 16	65	М	MDR	No formal education	Extended	No	

MDR, multidrug-resistant; P, patient; TB, tuberculosis; XDR, extensively drug-resistant.

quotes. Then, the researchers discussed and clarified the content of each audio-recording of the interview. We used an analysis system, based on the literature review and preliminary assessment of the collected qualitative data in the background of the research question. In the second stage, we generated some major themes, and then, further in-depth analyses of data were done to study the connection between these major themes. The results were presented to the research team to ensure that the experiences of the patients were accurately captured and reflected in the research.

Patient and public involvement

Patients were not involved in the study design, methodology, recruitment and dissemination of findings.

RESULTS

Interviewed participants comprised 5 XDR and 11 MDR cases. The participants, ranging from 18 years to 65 years of age, were interviewed using a predesigned open-ended in-depth interview guide. Out of 16 patients, there were only 2 women as the majority of the patients with DR-TB were men. Most of these patients lacked formal education and only six patients completed primary schooling. Most of them were unable to perform any kind of work or household chores because of their disease (table 1). All participants were married staying with their families. The living condition of the participants was inconceivable, 9 out of 16 participants were living in the *kutcha* house with a single room without any ventilation (table 2). Wood/ crop residual was used for cooking on the *chulha* (hearth) inside the living room. The above-mentioned poor living

conditions significantly contributed to the predominance of TB among the tribal population. Patient narratives pointed out the struggles and difficulties of the journey which a patient with DR-TB has to undergo from diagnosis to treatment and are summarised in figure 1. The narratives of patients were broadly divided into six

Table 2 Sociodemographic characteristics of participants					
Characteristics	Category	Ν	Per cent		
Type of family	Nuclear	6	37.5		
	Extended	10	62.5		
Children	No child	0	0		
	Less than 2 children	4	25		
	More than 2 children	12	75		
Type of house	Kutcha	9	56.2		
	Semi-pucca	5	31.5		
	Pucca	2	12.5		
No of rooms in the	1	14	87.5		
house	More than 1	2	12.5		
Ventilation in living	No	12	75		
room	Yes	4	25		
TB history in	No history	11	68.7		
family	History of contact	5	31.2		
Mode/fuel for cooking	Chulha/wood	16	100		
TB, tuberculosis.					

TB, tuberculosis.




Figure 1 Thematic representation.

themes, where each theme is further divided into two subthemes—pretreatment and during treatment. Six themes and subthemes are presented in table 3, and important individual narratives are presented in box 1.

Pretreatment phase

Perception about disease

Lack of education in the patients and their family leads to several misbeliefs and misconceptions about the disease. A participant (P5) narrated his belief about the disease as "At home, my family members believed that if a person has TB he will die eventually (sukh sukh kar mar jata hai), people even say this to me..." One thing that everyone understood is that TB is a fatal disease and 14 out of 16 participants had seen death due to this disease either in their close family or in their village which is a traumatising experience and somehow plays a major role in depleting the confidence and fighting spirit of the patient against the disease. One of the major obstacles is the acceptance of the disease or to accept that they are suffering from it. During interviews, it was observed that the moment a patient comes to know that he/she is suffering from a disease, it is a very shocking and traumatising experience for him/her. A participant (P5) shared how difficult it was for him to believe that he is suffering from the disease, "When for the first time, I got the result of the test and came to know that I am suffering from the disease, I felt

as the ground is slipping beneath my feet (pair keneechai se zameen fisal gayi ho jaise)."

General physical health and other factors

Due to lack of awareness, many times patients quit treatment and do not complete the course, especially in DR cases. It is seen that the majority of the patients took anti-TB treatment before getting DR-TB. One such condition came out during the interview when a patient himself narrated about not taking medication properly as he (P4) started feeling better, "I took TB medication twice before, and last was six months ago. This is my third time taking medicine. I took medicines for about three months each time and as I started feeling better; I used to stop taking medicines. But now, I will complete the full course of treatment." The patients also mentioned that they did not understand the reason for their deteriorating health condition and faced many problems.

The study participants belong to resource-deprived areas and are mainly engaged as daily wage labourers, construction workers or doing farming-related work. The supervisors/landlords make them work tirelessly. When these workers are taken out to other places for work, they usually stay in close contact with other labourers working with them, and thus the chances of getting an infection and infecting others increase. Due to illiteracy, lack of awareness about the disease and their belief system, they approach local healers/private practitioners for treatment. One such participant revealed that he was taking treatment from a private doctor for a long time; every time he was getting temporary relief after taking medicines. Further, due to poor access to the healthcare facility and lack of knowledge, people do not know where exactly to go for the right treatment and what is the right treatment. Many times, patients, due to lack of information and misbeliefs, fall into the trap of non-medical practitioners (faith healers, flick burnt (ojaha)) who are easy to approach.

Treatment phase

Experiences at the time of treatment

Anti-TB drugs are known for their adverse side-effects. Participants shared their experiences about their suffering and narrated how hard it was for them to overcome them. Side-effects especially nausea, vomiting, breathlessness, anxiety and insomnia were commonly observed; whereas breathlessness, anxiety and nausea were major side-effects observed in the case of patients with DR-TB. However, social stigma was not an obstruction in TB diagnosis or treatment in the study population, as 15 out of 16 participants told that they never faced any stigmatisation and family members took care of them without any discrimination. As one patient (P8) narrated: "I never faced any stigmatization, people never behaved weird/strange with me. I attend all the family functions and social gatherings." Another patient (P12) reported, "My family takes good care of me and relatives use to visit me for asking about my health every now and then, they never showed

Table 3 Representation of themes

	Subthemes					
Themes	Pretreatment phase	Treatment phase				
Challenges	The time from diagnosis to treatment is a big challenge ways, be it emotionally, physically or financially.	in a patient's life which breaks him in all possible				
Physical challenges	 Physical symptoms discomfit normal activities of daily life. Like household chores or even taking care of personal chores. 	 Adverse effects of drugs are experienced by ma patients. These side-effects adversely impact th life of the patient. Multiple drugs/pill burden is also reported to be difficult to tolerate by the patients. 				
Health system challenges	 Healthcare facilities are difficult to reach because of distance. The attitude of health facility personnel. No proper channel or awareness about the facility. 	 The facilities at DR-TB centres are not sufficient and the distance that one has to travel to reach centre is about 120–240 km. The facilities like place and food in the hospital ward are not proper. The number of days to be admitted in a hospital treatment initiation is also longer (15 days). 				
Economic challenges	 Loss of income as no work due to poor physical health. 	Until the time patient gets DBT money for treatmonly, one has to pay the large amount out of his pocket for travelling, food and daily necessities.				
Emotional and psychological challenges	Due to physical ill health, he/she is dependent on others for the daily necessities, so emotional state is devastated.	Once a patient gets information about his TB disease particularly DR status, the hope of living just vanishes as they consider it to be a fatal disease with no cure.				
Social challenges	 Lack of involvement in social gatherings due to poor health conditions. 	 Stigmatisation is not reported by the participant but they avoid social gatherings due to their poor health condition. 				

any discrimination because of this disease." Only one participant (P10) reported some discrimination by family members, as he told: "As such no one directly say something to me, but from their actions, I can feel that they discriminate me, and they also keep distance from me." Many patients also reported a high pill burden—taking 9–12 tablets at a time as the reason for non-compliance. Fear of injections was also mentioned among one of the reasons restricting them to adhere to the treatment. A patient (P9) reported, "Initially, when treatment started, taking medicines and especially injection daily was horrific, I used to get mad and was unable to do anything and even unable to sit. So, I decided to go for injections on alternate days, thus somehow, I managed to cope with my condition."

Challenges for treatment adherence Physical weakness

Many patients reported that they have become very weak due to the disease and are unable to practise their livelihood and support their families. The majority of patients are daily wage labourers and used to work in the field requiring lots of physical strength and energy. A patient (P4) narrated, "There was a time when I used to work hard in the field from morning till evening, even sometimes at night and also used to go to the jungle to collect wood for cooking. But this disease has made me so helpless, now I can't think of doing my daily routine works."

Financial burden

One important theme which came out of the interviews is the financial hardships on the patients especially in poor people, as the disease condition shatters their livelihood severely. A patient (P10) reported, "We spent around Rs.3000 per visit to Gwalior (private treatment) and had to visit regularly for six months. But then I stopped treatment as I had no money to go there regularly."

Treatment at the healthcare facility

Patients reported that they did not get medicine from the health facility/drug provider for continuing their treatment. Lack of access to the healthcare facility, long distances and long duration to reach the healthcare facility made it difficult for the patients to avail proper treatment. Patients are required to go to the DR-TB centre for initiating XDR treatment which is around 120–240 km from the village/district hospital and thus had to make huge out-of-pocket expenditures. Many patients reported this financial burden as well as poor facilities at the DR-TB centre. A patient (P1) reported, "Nobody can stay in the hospital (DR-TB facility). It is not cleaned and in morning hours nobody is there to look after the patients, only at

Box 1 Illustrative quotations of the study participants

Pretreatment phase

Perception about disease

- At home, my family members believed that if a person has TB he will die eventually (sukh sukh kar mar jata hai), people even say this to me... (P5)
- From this disease people slowly-slowly die (ghut ghut ke marr jate hai). (P4)
- There is nobody in my family, except myself and my wife. My brother and sister-in-law died of the same disease, their children are with us. Three people in my family died of the same disease. (P9)
- My father was the first one to suffer from TB, then my mother got this illness and now I got this disease. It is persisting in my family, my father died because of this disease. (P11)
- When for the first time I got the result of the test and came to know that I am suffering from the disease, I felt as if the ground was slipping beneath my feet (pair ke neeche se zameen fisal gayi ho jaise). (P5)
- One year back I went to Gwalior, where I heard for the first time that I am suffering from this disease, and was shocked thinking that how could this happen to me. (P10)

General physical health and other factors

- I took TB medication twice before, and the last was six months ago. This is my third time of taking medicine. I took these for about three months each time and as I started feeling better; I used to stop taking medicines. But now, I will complete a full course of treatment. (P4)
- Two years back, my physical condition worsened too much and I was not able to stand or walk for my daily necessity, I needed somebody's help. (P9)
- Around six years back, I used to work as a labour and had a fever for days. Whenever I complained about fever and weakness to the in-charge (Seth), he used to give me a green cover tablet (hare panni ki dawai). When I got physically weak, he kicked me out of work (mujhe kaam se bahar nikal diya). (P8)
- About 4–5 years back, when I was working in Jaipur, there was a co-worker (labour) who used to stay with me in the same plot, he suffered from TB and was taking medicine at that time, I feel that I might have got this infection from him. (P5)
- For about a year I was on private treatment. I used to get fever and cough and the doctor gave me some medicine for these. After getting temporary relief I used to stop taking those medicines, then my health condition use to become the same as before. (P4)
- I went to Kasba in Rajasthan state, earlier I got an herb (jadibooti) for my illness. After performing the ritual with clove, lemon, and chicken, they gave me one amulet (tabeej). I strongly believe that only after getting the amulet (Tabeej), medicine started working on my body. Earlier I took treatment many times but nothing was effective. (P9)

Treatment phase

Experiences at the time of treatment

- Still, I feel breathlessness, nausea, and feverish. This is too difficult for me to bear, I feel very anxious. (P12)
- When I came back from the DR-TB center and took medicine at home, that was the hardest time for me and it lasted for around 10–15 days. As soon as I used to take medicine, I felt very uneasy with nausea and dizziness. At the DR-TB center also I was taking the same medicine but it didn't happen there. But when I came back home, it all started happening. After few days, eventually, it got better, now I don't feel like that anymore. (P5)

Continued

Box 1 Continued

- I feel severe nausea and anxiety while taking these medicines, 12 tablets are to be taken daily. (P4)
- It was very difficult to take 10 tablets all together at a time that too on empty stomach, I use to feel anxiety, breathlessness soon after taking medicine. (P11)
- Initially, when treatment started, taking medicines and especially injections daily was horrific, I used to get mad and was unable to do anything and even unable to sit. So, I decided to go for the alternate day for injection, thus somehow, I managed to cope with my condition. (P9)
- When I started treatment, I used to take a large number of tablets. I used to feel the heat inside and nausea, urine used to be red, but then also I completed all the dosages. Only injections were left as it was too painful for me to take injections daily. (P1)

Challenges for treatment adherence

- If I work a little bit or carry 10–20 kg of weight then within few minutes I start feeling breathlessness. I cannot help with anything at home, even not in household chores. (P5)
- There was a time when I used to work hard in the field from morning till evening, even sometimes at night and also used to go to the jungle to collect wood for cooking. But this disease has made me so helpless, now even I can't think of doing my daily routine works. (P4)

Financial burden

- I took treatment for around 6 months from Jaipur and Sawai Madhopur (private treatment), there they never disclosed this disease and used to tell that there is some problem in the X-ray (X-Ray me kharabi hai) and will get better within 3–4 months of medication. I spent a lot of money during each visit. (P5)
- During the last 2 years, I have spent more than Rs.1 lakh for my and my daughter's treatment from many doctors and private hospitals in Gwalior including expenses for food and traveling. (P5)
- We spent around Rs.3000 per visit to Gwalior (private treatment) and had to visit regularly for six months. But then I stopped treatment as I had no money to go there regularly. (P10)

Treatment at healthcare facilities

- When I started taking medicine, after one box nobody gave me another one, even I asked the doctor he didn't give me, not even the Anganwadi people. (P11)
- I have personally visited many times, even I went to the district hospital for medicine but nobody gave us medicine. (wife of P11)
- Nobody can stay in the hospital (DR-TB facility). It is not cleaned and in morning hours nobody is there to look after the patients, only at day time some staff use to come. Most of the patients come from Morena and go back to their place on the same day. People who are from far places, only stay in the hospital because of their helplessness, as they have no other option (Koi aur suvidha hi nahi hai). (P1)
- There is no arrangement for food and water, even for testing, we have to go to private labs, where they charge us. Travel cost for reaching the hospital place is another burden. (P1)
- All tests were done from private; I had to pay for all the tests. It was the peak of summer and there was no water facility or fan/ cooler in the hospital. Not many patients as well. (P4)
- The facility here (district hospital) is better than DR-TB centre, where everyone listens to us and provides everything we want, there we have to ask several times, then only they listen. There we cannot talk to doctors directly, only attendants with us can talk to a doctor. They keep patients at distance. In the DR-TB

Continued

BMJ Open: first published as 10.1136/bmjopen-2020-044698 on 12 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Box 1 Continued

centre, they (health staff) hate patients. But in the district hospital, they never showed such kind of behavior to us. (P5) *Improvement in health*

- After taking medication, there is a lot of improvement, now I don't have bodyache, my appetite is also improved. These days, I eat more and also no cough or breathlessness, as I used to have before. (P1)
- Now when I go to bed in the night, I wake up directly in the morning, but earlier, I used to cough the whole night because of which I was not able to sleep at night. (P1)

DR-TB, drug-resistant tuberculosis; P, patient.

day time some staff use to come. Most of the patients come from Morena and go back to their place on the same day. People who are from far places, only stay in the hospital because of their helplessness, as they have no other option (Koi aur suvidha hi nahi hai)." Due to the distance and poor facilities in the hospitals (DR-TB centre), the participants mentioned that it would be more convenient if this facility is available at the district hospital itself or in some nearby health facility. Most of the participants were satisfied with the treatment provided in the district hospital. As one patient (P5) reported, "The facility here (district hospital) is better than DR-TB centre, everyone listens to us and provide everything we want, while there we have to ask several times and then only they listen. There we cannot talk to doctors directly, only attendants with us can talk to a doctor. They keep patients at distance. In the DR-TB centre, they (health staff) hate patients. But in the district hospital, they never showed such kind of behavior to us."

Improvement in health

Once the patient starts taking the right treatment, within few days he starts feeling the difference in his general health, and also improvement in the routine activities like eating, sleeping and also relief in symptoms. Many of the participants discussed their positive reflections of taking medicine and specified, "After taking medication there is a lot of improvement. Now I don't have bodyache and my appetite is also improved. These days, I eat more and also no cough or breathlessness, as I used to have before," a 50-year-old patient (P1) reported.

DISCUSSION

As per WHO's Global Tuberculosis Report 2019, most WHO regions and many high TB burden countries are not on track to reach the 2020 milestones of the End TB Strategy.¹ The situation is not different in India either. India accounted for the highest MDR-TB burden globally¹ and the constant increase in MDR-TB cases in the country is a matter of great concern as it poses a threat to TB control. This is especially relevant in disadvantaged population groups such as Saharia, a tribal community with an alarmingly high prevalence of TB.^{13 14} DR-TB is also emerging as a serious health problem in this tribe.⁴

The present qualitative study tries to understand issues related to the high TB burden and challenges in adherence to treatment in Saharia tribal community.

The current study was conducted among 16 DR-TB cases of the Saharia tribal community. Although the National TB Elimination Programme (formerly Revised National Tuberculosis Control Programme) has been operational for more than 15 years along with programmatic management of DR-TB from 2013 in this area, the findings of the study suggest that more concerted efforts are required especially at a grass-root level. The study highlights several challenges faced by patients with DR-TB belonging to a marginalised community from Central India. One important issue common to all the participants was their poverty and added financial burden due to the disease treatment of TB. The studies conducted in different settings also highlighted the 'catastrophic' costs associated with TB and DR-TB treatment despite the provision of free treatment.¹⁵¹⁶ Furin *et al*, in a study conducted in South Africa, reported a significant economic burden on patients with RR-TB and households due to the loss of income and the expenses for transportation.¹⁷ In India, although all notified patients with TB are entitled to cash transfer of 500 Indian rupees per month during the complete course of treatment under the direct benefit transfer (DBT) scheme, there are delays in transferring benefits. A study conducted in Western India reported that only 7.3% of patients received their first instalment within 2 months of treatment initiation.¹⁸ The delays in access to such grants are also reported by other workers.¹⁵ The economic support during the first few months of treatment is crucial and if linked with counselling, it improves treatment adherence and the chance of cure.¹⁹ The timely payment under DBT/economic support during the first few months of treatment with counselling shall go a long way in improving treatment compliance in patients with DR-TB in this marginalised community.

The majority of patients with DR-TB noted adverse effects to TB treatment. This is an important factor for treatment adherence, as has been mentioned by other authors.^{5 6 17} Many patients also noted the number of tablets, long duration of treatment and painful injections as the reason for non-adherence to the treatment. Similar findings are also reported by other authors in different settings.^{17 20 21} This highlights the importance of continuous counselling of the patients and their family members so that in the course of adverse effects, the patient does not leave the treatment midway.

The patients also reported various problems related to health facilities including the indifferent attitude of the staff and the services provided in DR-TB centres. The poor attention and even maltreatment by health staff; poor maintenance of the facility; lack of basic facilities such as drinking water, fan, etc; and no supply of medicines by health workers were some of the issues noted by them. Many studies also reported such issues in different population groups.^{20 22 23} The patients' and the community's perceptions about the disease, attitudes and beliefs about the treatment, and work-related issues also determine their response to TB-related services in this tribal community. The beliefs and practices related to TB are reported by other authors.^{23–26} The whole process of diagnosis and treatment of DR-TB is very tiring and traumatising for the individuals, as one has to undergo various phases leading to physical fatigue and mental tiredness. Fighting with the disease condition and overcoming anxiety and fear pose the biggest challenge in patients' life. Most of the patients have seen their kith and kin succumbing to TB, resulting in shattering of their confidence with the constant fear of death. Fear and denial of diagnosis as noted in the present study are also found in other studies.^{23 26 27}

The work-related issues included fear of losing the job, need to earn a living, taking care of family, etc, which are also reported in other studies.²²⁻²⁴ The belief in traditional healers for common ailments is also deeply rooted in the community. The easy availability close to their residence and the negligible cost of treatment also explain their preference for traditional healers. This study which was conducted among the most vulnerable sections of society revealed that due to lack of awareness, patients seek treatment from the places/persons where they get misguided, leading to further financial burden. It is not that the patient and his/her family do not take the disease seriously but many times they do not know where to go for the right treatment. Yellappa et al mentioned the impact of disease on a patient's family and caretakers' lives, as a family is one of the main sources of support during patients' treatment and recovery.²⁸ This highlights the need for involving the community in TB control activities as the disease impacts all the individuals associated with the patient.

Most of the participants in the study reported that they never experienced any kind of stigma or discrimination from family members or their community. This is in contrast to the findings of other studies carried out among patients with DR-TB in India^{5 21 24} and abroad.²⁸⁻³⁴ This indicates social acceptance of patients with TB in the community. However, patients noted that they choose to refrain from society and avoid social gatherings like weddings, religious functions, community meetings, etc due to their physical weakness. The social acceptance of patients with TB is encouraging and assumes importance as the TB burden is very high in this tribal community. Many studies have reported a strong influence of stigma resulting in non-adherence to treatment as they become demoralised due to weak family support.²¹⁻²³ Due to guilt and fear of getting isolated in the family and the community, patients may also hide their disease.^{22 26 27} It is also encouraging to note that many patients had a positive attitude towards treatment and mentioned that they got relieved of their symptoms and are feeling better with the treatment. Such patients can be effective ambassadors for motivating other patients and family members as they belong to the same community. A study in Ethiopia also reported a positive attitude of patients towards treatment.²

Our study has identified several problems faced by patients with DR-TB living in remote tribal areas by the means of various narratives by the participants where they opened up about the difficult experiences in the course of the disease. These are complex and dynamic with multiple factors affecting treatment adherence. The study mainly highlights social determinants of health like social and economic conditions and also the need for improvement in the healthcare facilities and infrastructure. This emphasises the importance of social factors that could affect individuals' ability to seek healthcare and adhere to a course of treatment.³⁰³¹ The long distance of the healthcare centre and lack of infrastructure increase patients' struggle to reach the facility in time, especially due to their occupation or other sociocultural obligations.^{32 33} The long-term outcomes in patients with DR-TB especially in patients with XDR-TB are usually poor, thus, putting close contacts and the community at risk of getting the infection.^{35 36} Thus, the threat of spreading the infection with DR strains is one of the major challenges particularly in disadvantaged populations as in the present study. To address these factors, a systematic multipronged approach would be required with a specific focus on 'patient-centred care' for patients with DR-TB as has been found useful in other studies.^{17 31}

Few methodological limitations need to be discussed. First, the sample was purposive and may not entirely represent the experiences and needs of patients with MDR/ XDR-TB in this community. Second, the patients were interviewed for their perceptions and experiences about TB and the available TB services retrospectively which may result in recall bias. We however tried to minimise the recall bias through interviewers' training in probing during interviews to facilitate precise replies. Though the findings of the study may not be generalised universally, these are relatable to any remote area and poverty-driven individual and can be generalised with any other similar study setting.

CONCLUSION

The study has important implications for TB policy and practice especially for disadvantaged communities living in remote tribal/rural areas. It provides an insight into the experiences and needs of patients with DR-TB belonging to the Saharia tribe and is useful in devising strategies to improve treatment adherence for this community. In tribal-dominated areas, health facilities need to be cohesive to the social and cultural beliefs of local populations so that they do not hesitate to approach these facilities for their diagnosis and treatment needs. Periodical counselling of patients is a must for proper treatment adherence and to gain their confidence in the treatment and medication process. DR-TB has far-reaching consequences not only on their physical health but also on their socioeconomic, psychological and emotional health. To achieve our goal of eliminating TB by 2025, we need to address the challenges faced by the patients and also their support networks. This emphasises the need for 'patient-centred care' where patients' needs are to be comprehended and prioritised.

Acknowledgements The authors would like to extend their gratitude towards the Director, ICMR-NIRTH, Jabalpur for the support in the study and also to all the participants who have given their time for the interview and believed in the authors for giving proper response. Last but not the least, thanks are due to all the district coordinators and field staff for their constant support.

Contributors SN, RKS and JB designed the study. SN, PM and MAL did data collection. SN, RKS and RY carried out the analysis. SN, VGR, RKS and JB wrote the manuscript. All the authors read and edited the manuscript.

Funding It is a substudy under the ongoing study on Intensified TB Control Project among the Saharia tribe, a PVTG in Madhya Pradesh. The main study is funded by the Government of Madhya Pradesh.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The present research is a part of an ongoing study that has been approved by the Institutional Ethics Committee (IEC) at ICMR NIRTH (approval reference number: NIRTH/IEC/2273/2016). The study objectives were explained to all participants and written informed consent for their participation and audio-recording were obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data supporting our finding are available with the investigators and would be available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Jyothi Bhat http://orcid.org/0000-0001-8788-2250

REFERENCES

- 1 World Health Organisation. Global tuberculosis report 2019. World health organisation, 2019. Available: https://www.who.int/tb/ publications/global_report/en/
- 2 World Health Organisation. The end TB strategy. World Health Organization, 2015. Available: https://www.who.int/tb/strategy/End_ TB_Strategy.pdf
- 3 World Health Organization. Drug-resistant TB: surveillance and response: supplement to global tuberculosis report 2014. World Health Organization, 2014. Available: https://apps.who.int/iris/handle/ 10665/137095
- 4 Prakash R, Kumar D, Gupta VK, et al. Status of multidrug resistant tuberculosis (MDR-TB) among the Sahariya tribe of North Central India. J Infect Public Health 2016;9:289–97.
- 5 Deshmukh RD, Dhande DJ, Sachdeva KS, *et al.* Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB centre in India. *PLoS One* 2015;10:e0135802.
- 6 Parmar MM, Sachdeva KS, Dewan PK, et al. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): evidence leading to policy enhancement. *PLoS One* 2018;13:e0193903.

- 7 Government of India. Annual report 2017-18. Ministry of tribal Affairs, government of India, 2018. Available: https://tribal.nic.in/ writereaddata/AnnualReport/AR2017-18.pdf
- 8 Rao VG, Gopi PG, Bhat J, *et al*. Pulmonary tuberculosis: a public health problem amongst the Saharia, a primitive tribe of Madhya Pradesh, central India. *Int J Infect Dis* 2010;14:e713–6.
- 9 Rao VG, Gopi PG, Yadav R, *et al.* Tuberculous infection in Saharia, a primitive tribal community of central India. *Trans R Soc Trop Med Hyg* 2008;102:898–904.
- 10 pp Bhat J, Rao VG, Sharma RK, et al. Investigation of the risk factors for pulmonary tuberculosis: A case-control study among Saharia tribe in Gwalior district, Madhya Pradesh, India. Indian J Med Res 2017;146:97–104.
- 11 Rao VG, Gopi PG, Bhat J, et al. Selected risk factors associated with pulmonary tuberculosis among Saharia tribe of Madhya Pradesh, central India. Eur J Public Health 2012;22:271–3.
- 12 Sharma RK, Rao VG, Yadav R, et al. Comparative yield of pulmonary tuberculosis different symptoms among Saharia tribe of Madhya Pradesh, India. Indian J community Med. In Press.
- 13 Rao VG, Bhat J, Yadav R, *et al.* Pulmonary tuberculosis a health problem amongst Saharia tribe in Madhya Pradesh. *Indian J Med Res* 2015;141:630–5.
- 14 Chakma T, Rao PV, Pall S. Survey of pulmonary tuberculosis in a primitive tribe of Madhya Pradesh. *Indian J Tubec* 1996;43:85–9.
- 15 Ramma L, Cox H, Wilkinson L, et al. Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis 2015;19:1513–9.
- 16 Foster N, Vassall A, Cleary S, et al. The economic burden of TB diagnosis and treatment in South Africa. Soc Sci Med 2015;130:42–50.
- 17 Furin J, Loveday M, Hlangu S, et al. "A very humiliating illness": a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa. BMC Public Health 2020;20:76.
- 18 Patel BH, Jeyashree K, Chinnakali P, et al. Cash transfer scheme for people with tuberculosis treated by the National TB programme in Western India: a mixed methods study. *BMJ Open* 2019;9:e033158.
- 19 Baral SC, Aryal Y, Bhattrai R, et al. The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot intervention studies. BMC Public Health 2014;14:46.
- 20 Jaiswal A, Singh V, Ogden JA, *et al.* Adherence to tuberculosis treatment: lessons from the urban setting of Delhi, India. *Trop Med Int Health* 2003;8:625–33.
- 21 Shringarpure KS, Isaakidis P, Sagili KD, et al. "When Treatment Is More Challenging than the Disease": A Qualitative Study of MDR-TB Patient Retention. *PLoS One* 2016;11:e0150849.
- 22 Harper M, Ahmadu FA, Ogden JA, *et al.* Identifying the determinants of tuberculosis control in resource-poor countries: insights from a qualitative study in the Gambia. *Trans R Soc Trop Med Hyg* 2003;97:506–10.
- 23 Khan A, Walley J, Newell J, *et al.* Tuberculosis in Pakistan: sociocultural constraints and opportunities in treatment. *Soc Sci Med* 2000;50:247–54.
- 24 Greene JA. An ethnography of nonadherence: culture, poverty, and tuberculosis in urban Bolivia. *Cult Med Psychiatry* 2004;28:401–25.
- 25 Liefooghe R, Michiels N, Habib S, et al. Perception and social consequences of tuberculosis: a focus group study of tuberculosis patients in Sialkot, Pakistan. Soc Sci Med 1995;41:1685–92.
- 26 Demissie M, Getahun H, Lindtjørn B. Community tuberculosis care through "TB clubs" in rural North Ethiopia. Soc Sci Med 2003;56:2009–18.
- 27 Johansson E, Winkvist A. Trust and transparency in human encounters in tuberculosis control: lessons learned from Vietnam. *Qual Health Res* 2002;12:473–91.
- 28 Yellappa V, Lefèvre P, Battaglioli T, et al. Coping with tuberculosis and directly observed treatment: a qualitative study among patients from South India. BMC Health Serv Res 2016;16:283.
- 29 Tulloch O, Theobald S, Morishita F, et al. Patient and community experiences of tuberculosis diagnosis and care within a community-based intervention in Ethiopia: a qualitative study. *BMC Public Health* 2015;15:187.
- 30 Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. *Emerg Infect Dis* 2006;12:1389–97.
- 31 Horter S, Stringer B, Reynolds L, et al. "Home is where the patient is": a qualitative analysis of a patient-centred model of care for multidrug resistant tuberculosis. BMC Health Serv Res 2014;14:81.
- 32 Hargreaves JR, Boccia D, Evans CA, et al. The social determinants of tuberculosis: from evidence to action. Am J Public Health 2011;101:654–62.

Open access

- 33 Lewis CP, Newell JN. Improving tuberculosis care in low income countries – a qualitative study of patients' understanding of "patient support" in Nepal. *BMC Public Health* 2009;9:190.
- 34 Craig GM, Daftary A, Engel N, et al. Tuberculosis stigma as a social determinant of health: a systematic mapping review of research in low incidence countries. *Int J Infect Dis* 2017;56:j.ijid.2016.10. 011:90–100.
- 35 O'Donnell MR, Jarand J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010;153:516–22.
- 36 Pietersen E, Ignatius E, Streicher EM, et al. Long-Term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014;383:1230–9.